Name of the Formulation	Licensed Annual capacity - (COB Licence 1971)	Highest Prodn. during the 1st 5 years
3. *Tablets* :		
(a) Bevidox (b) Cecon '500' (c) Erythrocin 100 mg. (d) Erythrocin 250 gm. (e) Iberol (f) Optilets (g) Optilets M (h) Primilets (i) Sucaryl (j) Surbex Sugar Coated (k) Surbex T	100 (one hundred million) tablets	141.2 millions.
4. *Capsules* :		
(a) Nembutal (b) Tridione	800.000 (Eight lakh) Numbers	242.8 '000 Nos.
5. *Granules* :		
(a) Erythoricin (b) Pentothal Sodium	5,737 (Five thousand seven hundred thirty seven) Kgs.	20902.6 kgs.

(h) and (i) The re-endorsement is subject to the condition that the company shall reach the ratio of 1:10 between the value of production of bulk drugs and formulations within a period of 2 years from the date of re-endorsement of capacities failing which the company shall have to export their entire formulations or such portion of the formulation which is beyond the ratio of 1:10.

Vacancies of High Court Judges in J & K

2306. SHRI GHULAM RASOOL KAR: Will the Minister of LAW AND JUSTICE be pleased to state:

(a) whether Government of the State of Jammu and Kashmir have recently recommended for the creation of another two posts of Judges in the High Court for Jammu and Kashmir State;

(b) whether it is a fact that there already exists one vacancy of a judge in that High Court; and

(c) whether the recommendations of the State Government are likely to be accepted and vacancies filled up at the earliest?

THE MINISTER OF STATE IN THE MINISTRY OF LAW AND JUSTICE (SHRI H. R. BHARDWAJ): (a) No such proposal has been received.

(b) Yes, Sir.

(c) The matter of filling up the existing vacancy is engaging the attention of the Government in consultation with the State Government.

Non-utilisation of capacity for the production of drug by I.D.P.L.

2307. SHRI BHAGATRAM MANHAR: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Unstarred Question 559 in the Rajya Sabha on the 6th May, 1985 and state:

(a) what are the reasons for non-utliisation of capacity available with IDPL for the manufacture of Glybenclamide;

(b) whether IDPL is marketing any formulation based on this drug; if so, the name of the formulation, the price fixed for each pack and strength;